Table 4.
A summary of discrete risk ratio estimates for diagnosed specific delays in development with increasing exposure to organic mercury (Hg) from Thimerosal-containing hepatitis B vaccine administration within the first 6 months of life.
| Exposure | Number diagnosed with specific delays in development (%) | Number of individuals in the cohort | Outcome measurement |
|---|---|---|---|
| 0 μg Organic Hg (reference dose) | 31 (1.701) | 1822 | |
| 12.5 μg Organic Hg | 21 (2.873) | 731 | |
| Relative risk (95% CI) | 1.669 (0.971–2.864) | ||
| p | 0.096 | ||
| Attributable risk (95% CI) | 0.0112 (−0.000606–0.0264) | ||
| Population attributable risk % (95% CI) | 16.191 (−2.355–34.737) | ||
| 25 μg Organic Hg | 1262 (3.761) | 33,557 | |
| Relative risk (95% CI) | 2.166 (1.526–3.0814) | ||
| p | <0.001 | ||
| Attributable risk (95% CI) | 0.0195 (0.0124–0.0249) | ||
| Population attributable risk % (95% CI) | 52.551 (36.192–68.910) | ||
| 37.5 μg Organic Hg | 641 (4.670) | 13,725 | |
| Relative risk (95% CI) | 2.667 (1.872–3.808) | ||
| p | <0.001 | ||
| Attributable risk (95% CI) | 0.0279 (0.0203–0.0340) | ||
| Population attributable risk % (95% CI) | 59.622 (45.865–73.379) |
CI = confidence interval.